Candel Therapeutics, Inc. (CADL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Candel Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Candel Therapeutics, Inc. (CADL) has returned -13.27% so far this year and -13.27% over the past 12 months.

Based on dividend-adjusted daily data since Jul 27, 2021, CADL's average daily return is +0.32%, while the average monthly return is +5.54%. At this rate, your investment would double in approximately 1.1 years.

Historically, 42% of months were positive and 58% were negative. The best month was Apr 2024 with a return of +346.2%, while the worst month was Jan 2022 at -45.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.

On a daily basis, CADL closed higher 47% of trading days. The best single day was Apr 4, 2024 with a return of +281.0%, while the worst single day was Dec 13, 2024 at -31.1%.

Candel Therapeutics, Inc. has an annualized alpha of 98.06%, beta of 1.16, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 28, 2021.

• This stock tended to rise when S&P 500 Index fell (downside capture of -17.39%), but participation in market rallies was also limited (-27.57%) — a profile typical of counter-cyclical assets.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CADL ranks 30 for risk / return — below 30% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Candel Therapeutics, Inc. (CADL) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Candel Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Candel Therapeutics, Inc. was 94.33%, occurring on Nov 3, 2023. Recovery took 132 trading sessions.

The current Candel Therapeutics, Inc. drawdown is 65.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Candel Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Candel Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.